Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-6-25
pubmed:abstractText
Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease). LRRK2 contains leucine-rich repeats, a GTPase domain, a COR [C-terminal of Roc (Ras of complex)] domain, a kinase and a WD40 (Trp-Asp 40) motif. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly. We undertook a KESTREL (kinase substrate tracking and elucidation) screen in rat brain extracts to identify proteins that were phosphorylated by an activated PD mutant of LRRK2 (G2019S). This led to the discovery that moesin, a protein which anchors the actin cytoskeleton to the plasma membrane, is efficiently phosphorylated by LRRK2, at Thr558, a previously identified in-vivo-phosphorylation site that regulates the ability of moesin to bind actin. LRRK2 also phosphorylated ezrin and radixin, which are related to moesin, at the residue equivalent to Thr558, as well as a peptide (LRRKtide: RLGRDKYKTLRQIRQ) encompassing Thr558. We exploited these findings to determine how nine previously reported PD mutations of LRRK2 affected kinase activity. Only one of the mutations analysed, namely G2019S, stimulated kinase activity. Four mutations inhibited LRRK2 kinase activity (R1941H, I2012T, I2020T and G2385R), whereas the remainder (R1441C, R1441G, Y1699C and T2356I) did not influence activity. Therefore the manner in which LRRK2 mutations induce PD is more complex than previously imagined and is not only caused by an increase in LRRK2 kinase activity. Finally, we show that the minimum catalytically active fragment of LRRK2 requires an intact GTPase, COR and kinase domain, as well as a WD40 motif and a C-terminal tail. The results of the present study suggest that moesin, ezrin and radixin may be LRRK2 substrates, findings that have been exploited to develop the first robust quantitative assay to measure LRRK2 kinase activity.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-10212266, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-10436021, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-10847681, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-10970850, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-11788735, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-12011437, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-12154370, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-12198158, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-12471243, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-14654223, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-15183186, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-15541308, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-15541309, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16083279, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16157908, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16157909, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16204178, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16269541, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16321986, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16336195, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16406842, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16616379, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16750377, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16879967, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-16966681, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-17114044, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-17200152, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-17222580, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-7579708, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-7612961, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-8089177, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-9456324, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-9786954, http://linkedlifedata.com/resource/pubmed/commentcorrection/17447891-9856983
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1470-8728
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
405
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
307-17
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
pubmed:affiliation
MRC Protein Phosphorylation Unit, MSI/WTB Complex, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't